Simone Brixius-Anderko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone Brixius-Anderko has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Frank Hannemann
Department of Biochemistry Saarland University Saarbrücken Germany
8 shared publications - Rita Bernhardt
Institut für Biochemie, Fachbereich Biologie, Naturwissenschaftlich-Technische Fakultät, Universität des Saarlandes, Saarbrücken, Germany
8 shared publications Bjoern Brixius
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania
5 shared publications- Lina Schiffer
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
5 shared publications - Emily E. Scott
Departments of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA; Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA; Biological Chemistry and the Programs in Chemical Biology and Biophysics, University of Michigan, Ann Arbor, MI 48109, USA
3 shared publications Rita Bernhardt
Saarland University, Saarbruecken, Germany
3 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (7) , 100329
Cytochrome P450–mediated metabolism of K31, a Ko143-derived ATP-binding cassette subfamily G member 2 inhibitor
- 20 May 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (7) , 100329
Open AccessCytochrome P450–mediated metabolism of K31, a Ko143-derived ATP-binding cassette subfamily G member 2 inhibitor
- Open Access
- 17 December 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (1) , 100221
On the interface of fatty acid metabolism: A crosstalk between fatty acid ω-hydroxylase CYP4F11 and fatty acid desaturase 2 in non–small cell lung cancer
- 17 December 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (1) , 100221
Open AccessOn the interface of fatty acid metabolism: A crosstalk between fatty acid ω-hydroxylase CYP4F11 and fatty acid desaturase 2 in non–small cell lung cancer
- Open Access
- 30 October 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (12) , 100193
Mycobacterium abscessus CYP123 is a steroid hydroxylase with an implication in host infection
- 30 October 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (12) , 100193
Open AccessMycobacterium abscessus CYP123 is a steroid hydroxylase with an implication in host infection
- Open Access
- 9 October 2025
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 274, 113105
How evolution shaped the structure of steroidogenic cytochrome P450 11A
- 9 October 2025
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 274, 113105
Open AccessHow evolution shaped the structure of steroidogenic cytochrome P450 11A
- Open Access
- 29 September 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (11) , 100176
Functional studies on the cytochrome P450 splice variants CYP4F3A and CYP4F3B unveil the basis for their distinct physiological functions
- 29 September 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (11) , 100176
Open AccessFunctional studies on the cytochrome P450 splice variants CYP4F3A and CYP4F3B unveil the basis for their distinct physiological functions
- Open Access
- 27 August 2025
- Published by The Royal Society in Open Biology
- Vol. 15 (8) , 250115
The curious family of cytochrome P450 4F fatty acid ω-hydroxylases: recent developments in their function and relevance for human health
Cytochrome P450 enzymes (CYP, P450) are indispensable for human health and catalyse a plethora of reactions contributing to the clearance of xenobiotics, steroid and bile acid biosynthesis, and the functionalization of vitamins in the human body. The family of CYP4F fatty acid ω-hydroxylases consists of five isoforms, CYP4F2, CYP4F3A, CYP4F3B, CYP4F11 and CYP4F22, which share a high amino acid sequence similarity but assume different physiological functions in humans. While CYP4F2 and CYP4F3B are the major enzymes producing a lipid mediator from arachidonic acid, CYP4F3A inactivates leukotriene B4 as anti-inflammatory response, CYP4F11 is capable of effectively metabolizing drugs, and CYP4F22 contributes to a healthy skin barrier. In this review, we provide an overview of recent developments in CYP4F function and discuss potential future directions underlining their growing relevance in human health and disease.
- 27 August 2025
- Published by The Royal Society in Open Biology
- Vol. 15 (8) , 250115
Open AccessThe curious family of cytochrome P450 4F fatty acid ω-hydroxylases: recent developments in their function and relevance for human health
Cytochrome P450 enzymes (CYP, P450) are indispensable for human health and catalyse a plethora of reactions contributing to the clearance of xenobiotics, steroid and bile acid biosynthesis, and the functionalization of vitamins in the human body. The family of CYP4F fatty acid ω-hydroxylases consists of five isoforms, CYP4F2, CYP4F3A, CYP4F3B, CYP4F11 and CYP4F22, which share a high amino acid sequence similarity but assume different physiological functions in humans. While CYP4F2 and CYP4F3B are the major enzymes producing a lipid mediator from arachidonic acid, CYP4F3A inactivates leukotriene B4 as anti-inflammatory response, CYP4F11 is capable of effectively metabolizing drugs, and CYP4F22 contributes to a healthy skin barrier. In this review, we provide an overview of recent developments in CYP4F function and discuss potential future directions underlining their growing relevance in human health and disease.
- Open Access
- 16 November 2023
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (2) , 69-79
Deciphering the Role of Fatty Acid–Metabolizing CYP4F11 in Lung Cancer and Its Potential As a Drug Target
Lung cancer is the leading cause of cancer deaths worldwide. We found that the cytochrome P450 isoform CYP4F11 is significantly overexpressed in patients with lung squamous cell carcinoma. CYP4F11 is a fatty acid w-hydroxylase and catalyzes the production of the lipid mediator 20-hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid. 20-HETE promotes cell proliferation and migration in cancer. An inhibition of 20-HETE-generating cytochrome P450 enzymes has been implicated as novel cancer therapy for more than a decade. However, the exact role of CYP4F11 and its potential as drug target for lung cancer therapy has not been established yet. Thus, we performed a transient knockdown of CYP4F11 in the lung cancer cell line NCI-H460. Knockdown of CYP4F11 significantly inhibits the lung cancer cell proliferation and migration while the 20-HETE production is significantly reduced. For biochemical characterization of CYP4F11-inhibitor interactions, we generated recombinant human CYP4F11. Spectroscopic ligand binding assays were conducted to evaluate CYP4F11 binding to the unselective CYP4A/F inhibitor HET0016. HET0016 shows high affinity to recombinant CYP4F11 and inhibits CYP4F11-mediated 20-HETE production in vitro with a nanomolar IC50. Cross evaluation of HET0016 in NCI-H460 cells shows that lung cancer cell proliferation is significantly reduced together with 20-HETE production. However, HET0016 also displays antiproliferative effects which are not 20-HETE mediated. Future studies aim to establish the role of CYP4F11 in lung cancer and the underlying mechanism and investigate the potential of CYP4F11 as a therapeutic target for lung cancer. Significance Statement Lung cancer is a deadly cancer with limited treatment options. The cytochrome P450 4F11 (CYP4F11) is significantly upregulated in lung squamous cell carcinoma. A knockdown of CYP4F11 in a lung cancer cell line significantly attenuates cell proliferation and migration with reduced production of the lipid mediator 20-HETE. Studies with the unselective inhibitor HET0016 shows a high inhibitory potency of CYP4F11-mediated 20-HETE production using recombinant enzyme. Overall, our studies show the potential of targeting CYP4F11 for new transformative lung cancer treatment.
- 16 November 2023
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (2) , 69-79
Open AccessDeciphering the Role of Fatty Acid–Metabolizing CYP4F11 in Lung Cancer and Its Potential As a Drug Target
Lung cancer is the leading cause of cancer deaths worldwide. We found that the cytochrome P450 isoform CYP4F11 is significantly overexpressed in patients with lung squamous cell carcinoma. CYP4F11 is a fatty acid w-hydroxylase and catalyzes the production of the lipid mediator 20-hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid. 20-HETE promotes cell proliferation and migration in cancer. An inhibition of 20-HETE-generating cytochrome P450 enzymes has been implicated as novel cancer therapy for more than a decade. However, the exact role of CYP4F11 and its potential as drug target for lung cancer therapy has not been established yet. Thus, we performed a transient knockdown of CYP4F11 in the lung cancer cell line NCI-H460. Knockdown of CYP4F11 significantly inhibits the lung cancer cell proliferation and migration while the 20-HETE production is significantly reduced. For biochemical characterization of CYP4F11-inhibitor interactions, we generated recombinant human CYP4F11. Spectroscopic ligand binding assays were conducted to evaluate CYP4F11 binding to the unselective CYP4A/F inhibitor HET0016. HET0016 shows high affinity to recombinant CYP4F11 and inhibits CYP4F11-mediated 20-HETE production in vitro with a nanomolar IC50. Cross evaluation of HET0016 in NCI-H460 cells shows that lung cancer cell proliferation is significantly reduced together with 20-HETE production. However, HET0016 also displays antiproliferative effects which are not 20-HETE mediated. Future studies aim to establish the role of CYP4F11 in lung cancer and the underlying mechanism and investigate the potential of CYP4F11 as a therapeutic target for lung cancer. Significance Statement Lung cancer is a deadly cancer with limited treatment options. The cytochrome P450 4F11 (CYP4F11) is significantly upregulated in lung squamous cell carcinoma. A knockdown of CYP4F11 in a lung cancer cell line significantly attenuates cell proliferation and migration with reduced production of the lipid mediator 20-HETE. Studies with the unselective inhibitor HET0016 shows a high inhibitory potency of CYP4F11-mediated 20-HETE production using recombinant enzyme. Overall, our studies show the potential of targeting CYP4F11 for new transformative lung cancer treatment.
- Open Access
- 12 October 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Nothing wrong with me
An assistant professor and group leader explains how being diagnosed with autism in her early 40s changed her approach to being a scientist.
- 12 October 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessNothing wrong with me
An assistant professor and group leader explains how being diagnosed with autism in her early 40s changed her approach to being a scientist.
- Open Access
- 14 September 2023
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 21 (9) , e3002291
Supporting nonlinear careers to diversify science
Nonlinear careers through academia are increasingly common, but funding agencies and search committees penalize these paths. Why do scientists stray from the beaten path, how do they contribute to science, and how do we level the playing field?
- 14 September 2023
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 21 (9) , e3002291
Open AccessSupporting nonlinear careers to diversify science
Nonlinear careers through academia are increasingly common, but funding agencies and search committees penalize these paths. Why do scientists stray from the beaten path, how do they contribute to science, and how do we level the playing field?
- 6 February 2023
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 48 (4) , 311-314
Recruiting women faculty through inclusive, family-friendly practices
- 6 February 2023
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 48 (4) , 311-314
Recruiting women faculty through inclusive, family-friendly practices